Rodon Natalia¹, Roman Ruth¹, Verdu Montse^1,3, Garcia Beatriz¹, Pujol Merce¹ and Puig Xavier^1,2,3.

¹BIOPAT.Biopatologia Molecular, SL, Grup Assistencia, Barcelona, Spain; ²Hospital de Barcelona, SCIAS, Grup Assistencia, Barcelona, Spain; ³Histopat Laboratoris, Barcelona, Spain.

Background: Mutations involving the epidermal growth factor receptor (EGFR) correlate with responsiveness to tyrosine kinase inhibitors (TKIs), which significantly improves patient survival in lung adenocarcinoma (AC). These mutations are described […]

Verdú M,¹ Colomer A,¹ Erill N,¹ Roman R,² Górriz M, ^1,2 Ibáñez R,¹ Cordon-Cardo C,¹ Puig X.^1,2

¹HISTOPAT Laboratoris, Barcelona, Catalonia, Spain & ²BIOPAT. Biopatologia Molecular, Grup Assistència.

Background: Non-small cell lung cancer (NSCLC) is classified in two main categories: adenocarcinoma (AC), which includes bronchioloalveolar carcinoma (BAC), and squamous cell carcinoma (SCC). Activating mutations and increased copy […]

Colomer A¹, Erill N¹, Verdú M², Román R ¹, Górriz M², Ibáñez R¹, Menoyo A¹, Cordon-Cardo C³, Puig X ^1,2.

¹BIOPAT, Grup Assistència, ²HISTOPAT Laboratoris, Barcelona, Spain; and ³Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, United States.

Background: Activating mutations of the EGFR gene were identified in tumors from patients with non small cell […]

M. J. Donovan, A. Kotsianti, A. Colomer, M. Verdú, M. Clayton, H. Pang, S. Hamann, C. Cordón-Cardó, X. Puig.

Background: The association of EGFR mutations with bronchoalveolar carcinoma (BAC) / non-small cell lung cancer (NSCLC) and the therapeutic and prognostic variability reported for lung cancer has reinforced the need for more accurate NSCLC sub-classification. The present […]